Jaguar8 commented on a stock · Jul 11, 2024 20:00

NEWS

Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC) 2024. The conference will be held in Philadelphia and online from July 28 to August 1, 2024. Sabirnetug, a humanized monoclonal antibody, has shown selective target engagement of toxic soluble amyloid beta oligomers (AβOs) in early symptomatic Alzheimer's disease (AD) patients. The company’s posters will discuss biomarker data, methods for detecting sabirnetug levels in cerebrospinal fluid (CSF), and patient experiences. The data aims to inform future clinical trials and potentially position sabirnetug as a best-in-class antibody treatment for early symptomatic AD.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

5965 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8163

Followers

Following

93K

Visitors